B
Bernard Charbonnel
Researcher at University of Nantes
Publications - 155
Citations - 14069
Bernard Charbonnel is an academic researcher from University of Nantes. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 40, co-authored 153 publications receiving 12375 citations. Previous affiliations of Bernard Charbonnel include Institut national de la recherche agronomique & Harvard University.
Papers
More filters
Journal ArticleDOI
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more
TL;DR: Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified; mortality rates from heart failure did not differ between groups.
Journal ArticleDOI
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).
Lars Rydén,Eberhard Standl,Malgorzata Bartnik,Greet Van den Berghe,John Betteridge,Menko-Jan de Boer,Francesco Cosentino,Bengt Jönsson,Markku Laakso,Klas Malmberg,Silvia G. Priori,Jan Östergren,Jaakko Tuomilehto,Inga Thrainsdottir,Ilse Vanhorebeek,Marco Stramba-Badiale,Peter Lindgren,Qing Qiao,Silvia G. Priori,Jean-Jacques Blanc,Andrzej Budaj,John Camm,Veronica Dean,Jaap W. Deckers,Kenneth Dickstein,John Lekakis,Keith McGregor,Marco Metra,João Morais,Ady Osterspey,Juan Tamargo,José Luis Zamorano,J.W. Deckers,Michel E. Bertrand,Bernard Charbonnel,Erland Erdmann,Ele Ferrannini,Allan Flyvbjerg,Helmut Gohlke,Jose Ramon Gonzalez Juanatey,Ian D. Graham,Pedro Filipe Monteiro,Klaus G. Parhofer,Kalevi Pyörälä,Itamar Raz,Guntram Schernthaner,Massimo Volpe,David Wood +47 more
TL;DR: Guidelines and Expert Consensus documents aim to present management and recommendations based on all of the relevant evidence on a particular subject in order to help physicians to select the best possible management strategies for the individual patient, suffering from a specific condition, taking into account not only the impact on outcome, but also the risk benefit ratio of a particular diagnostic or therapeutic procedure.
Journal ArticleDOI
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon,Richard Pratley,Samuel Dagogo-Jack,James P. Mancuso,Susan Huyck,Urszula Masiukiewicz,Bernard Charbonnel,Robert Frederich,Silvina Gallo,Francesco Cosentino,Weichung Shih,Ira Gantz,Steven G. Terra,David Z.I. Cherney,Darren K. McGuire +14 more
TL;DR: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events.
Journal ArticleDOI
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
TL;DR: In this article, the efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA 1c [A1C] ≥7 and ≤10%) with met formin alone.
Journal ArticleDOI
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K. McGuire,Weichung Shih,Weichung Shih,Francesco Cosentino,Bernard Charbonnel,David Z.I. Cherney,Samuel Dagogo-Jack,Richard E. Pratley,Michelle Greenberg,Shuai Wang,Susan Huyck,Ira Gantz,Steven G. Terra,Urszula Masiukiewicz,Christopher P. Cannon +14 more
TL;DR: This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.